Diabetes mellitus is associated with increased morbidity and long-term mortality in patients with heart failure with preserved ejection fraction.
What is the impact of comorbid diabetes mellitus on morbidity and mortality in patients with HFpEF, and what are the underlying pathological mechanisms?
This review highlights that comorbid diabetes in HFpEF is highly prevalent (approximately 45%) and is associated with worse clinical outcomes, emphasizing the need for targeted, patient-centered treatments.
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of HF, affecting over 3 million adults in the United States alone. HFpEF is a heterogenous syndrome. One important phenotype may be related to comorbid conditions, including diabetes mellitus (DM). DM has a prevalence of approximately 45% in HFpEF, but characteristics and outcomes of this population are poorly understood. In this review, the authors summarize data from several clinical trials of HFpEF therapeutics and provide original data from a large cohort using the Get With The Guidelines-HF registry, which together suggest that DM is associated with increased morbidity and long-term mortality in HFpEF. The authors then discuss several common pathological mechanisms in HFpEF and DM, including sodium retention, metabolic derangements, impaired skeletal muscle function, and potential therapeutic targets. As the understanding of comorbid HFpEF and DM improves, it is hoped clinicians will be better equipped to offer effective, patient-centered treatments.
McHugh et al. (Fri,) conducted a review in Heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus. Diabetes mellitus was evaluated on Morbidity and long-term mortality. Diabetes mellitus is associated with increased morbidity and long-term mortality in patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: